Aims and scope
Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that publishes original research papers, reviews and commentaries in cancer research, from bench to bedside.
Journal of Experimental & Clinical Cancer Research seeks manuscripts that include significant advances in basic cancer research and that offer a translational bridge from the laboratory to the clinic to open new avenues for the understanding, prevention, diagnosis and treatment of cancer.
Specific areas of interest include, but are not limited to: mechanisms of progression of the malignant phenotype and metastatic disease; molecular alterations or biomarkers that predict response or resistance to treatment; translational research in targeted therapies; personalized medicine; novel applications of bioinformatics and biostatistics; tumor immunotherapy; large-scale molecular characterization of human tumors and innovative methods with potential applicability to clinical investigation.
The following criteria provide an overview of the types of studies considered by the journal:
- Findings that have not been previously published in the same tumor model.
- Studies performed in multiple cell lines.
- Conclusions that are not representative of incremental findings.
- Studies that include a clearly written title and abstract that communicate the study's impact of significance to non-experts.
The online appearance of Journal of Experimental & Clinical Cancer Research allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community.
All articles published by Journal of Experimental & Clinical Cancer Research are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Journal of Experimental & Clinical Cancer Research you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Journal of Experimental & Clinical Cancer Research therefore levies an article-processing charge of £1470.00/$2300.00/€1875.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Journal of Experimental & Clinical Cancer Research are included in:
- Current contents
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Journal of Experimental & Clinical Cancer Research operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
After initial review for suitability, submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks.
All manuscripts submitted to Journal of Experimental & Clinical Cancer Research should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Journal of Experimental & Clinical Cancer Research
Articles in Journal of Experimental & Clinical Cancer Research should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. J Exp Clin Cancer Res [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Exp Clin Cancer Res 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Journal of Experimental & Clinical Cancer Research
Journal of Experimental & Clinical Cancer Research's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Journal of Experimental & Clinical Cancer Research offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Journal of Experimental & Clinical Cancer Research gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Journal of Experimental & Clinical Cancer Research are included in article alerts and regular email updates. Some may be highlighted on Journal of Experimental & Clinical Cancer Research’s pages and on the BioMed Central homepage.
In addition, articles published in Journal of Experimental & Clinical Cancer Research may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Experimental & Clinical Cancer Research. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Journal of Experimental & Clinical Cancer Research you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
Owned by the Association for International Promotion & Study in Tumors (APSIT)
Official journal of the Regina Elena National Cancer Institute, Italy
- Editorial Board
- Sign up for article alerts and news from this journal
2017 Journal Metrics
30 days to first decision for reviewed manuscripts only
28 days to first decision for all manuscripts
89 days from submission to acceptance
14 days from acceptance to publication
364 Altmetric Mentions